Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MYC serine 62 phosphorylation promotes its association with DNA double-strand breaks to facilitate repair and cell survival under genotoxic stress.

Genes & development·2026
Same author

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
Same author

Transplant Center Treatment in Emergency General Surgery Patients With a Solid-Organ Transplant.

Annals of surgery·2026
Same author

CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer.

Oncogene·2026
Same author

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A.

Nature communications·2026

Related Experiment Video

Updated: Jul 2, 2026

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort

Rashid K Sayyid1, Raj Tiwari2, Bo Zhang3

  • 1University of Arizona Tucson United States.

Cancer Research Communications
|June 30, 2026
PubMed
Summary

Proton pump inhibitor (PPI) use was not linked to a higher risk of prostate cancer (PCa) diagnosis or severity in older men. After accounting for healthcare visits and PSA tests, PPI use showed no independent association with PCa development.

Related Experiment Videos

Last Updated: Jul 2, 2026

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

Area of Science:

  • Oncology
  • Gastroenterology
  • Epidemiology

Background:

  • Proton pump inhibitors (PPIs) are widely used medications.
  • Previous studies suggested a potential link between PPI use and increased prostate cancer (PCa) risk.
  • The association requires further investigation in large, real-world cohorts.

Purpose of the Study:

  • To investigate the association between cumulative proton pump inhibitor (PPI) use and prostate cancer (PCa) diagnosis and outcomes.
  • To evaluate the impact of PPI use on PCa risk in a biopsy-naïve cohort of older men.

Main Methods:

  • Retrospective cohort study using province-wide administrative data from Ontario, Canada (2003-2018).
  • Inclusion criteria: men aged ≥66 years with no prior PCa diagnosis, biopsy, or treatment, and no PPI/H2-blocker use in the preceding year.
  • Analysis involved univariable/multivariable logistic regression and complementary log-log modeling to assess time to PCa diagnosis and outcomes.

Main Results:

  • Cumulative PPI use was initially associated with lower PCa diagnosis rates (HR 0.75).
  • After adjusting for healthcare utilization (GP visits, PSA tests), this association disappeared (HR 0.99).
  • No association was found between PPI use and clinically significant or high-grade PCa. PPI use was linked to lower rates of androgen deprivation therapy or orchiectomy.

Conclusions:

  • Cumulative proton pump inhibitor (PPI) use is not independently associated with an increased risk of prostate cancer (PCa) diagnosis.
  • Findings suggest that confounding factors, such as healthcare-seeking behavior, may explain previous associations.
  • PPI use does not appear to influence the risk of developing clinically significant or high-grade prostate cancer.